Has Jane Mattei, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,155 in general payments to Jane Mattei, MD across 30 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jane Mattei, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jane Mattei, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jane Mattei, MD

Medical Oncology · San Antonio, TXNPI 1821564915

Payments from drug & device makers

$4,155in general payments, 2019–2025

Across 30 payments — averaging $138.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Immunocore Limited$3K
Astellas Pharma US Inc$345
Pfizer$220
Caris MPI, Inc.$171
EMD Serono, Inc.$117
Array Biopharma Inc$114
plus $144 from 2 others

What the payments were for

Speaking & faculty fees$2,00048%
Travel & lodging$75518%
Food & beverage$1,12327%
Education$2777%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Immunocore Limited	8	$3,043
Astellas Pharma US Inc	5	$345
Pfizer	7	$220
Caris MPI, Inc.	1	$171
EMD Serono, Inc.	1	$117
Array Biopharma Inc	5	$114
Seagen Inc.	1	$93
Regeneron Healthcare Solutions, Inc.	2	$51

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,155 in reported general payments places this provider in the 30th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$1,756,109

Medicare patients

293

Services billed

56,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	28	$1,067
Prochlorperazine Maleate	23	$809
Ondansetron Hcl	35	$623
Triamcinolone Acetonide	13	$121
Levothyroxine Sodium	32	$80
Prednisone	13	$37

Paid to pharmacies, not to this prescriber.

Other medical oncology in San Antonio

Amita PatnaikSan Antonio$17.8M
Anthony TolcherSan Antonio$15.9M
Sukeshi AroraSan Antonio$9.1M
John SarantopoulosSan Antonio$9M
Virginia KaklamaniSan Antonio$5.5M
Lei ZhengSan Antonio$5.3M
Hagop KantarjianHouston$100.5M
Timothy YapHouston$56.7M
Yasir ElaminHouston$41.3M
David HongHouston$31.6M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →